Search PubMed⌕ Search

Biomedical subjects

E Vellenga

Publications and source records attributed to E Vellenga.

At least 217 records · Page 12Linked to original sources

Plasma beta-thromboglobulin in normal pregnancy and pregnancy-induced hypertension.

Plasma beta-thromboglobulin (BTG) was measured in 25 patients with pregnancy-induced hypertension (PIH), 7 of whom had severe PIH, and in 23 healthy gravidae. Also platelet counts, spontaneous platelet aggregation in vitro, and coagulation studies such as fibrinogen, fibrinogen degradation products and antithrombin III (AT III) were carried out: fetal outcome was judged by birthweight, placental weight and venous umbilical pH. Plasma BTG values of the PIH and severe PIH patients were significantly higher than those of the controls (P less than 0.05), suggesting enhanced platelet activation in the former. Compared with the controls, the entire PIH group was found to have significantly lower AT III values (P less than 0.05), more positive protamine sulphate tests (P less than 0.025), and higher plasma urate concentrations (P less than 0.01), but increased BTG values were more often observed than abnormal coagulation tests. No relationship could be demonstrated between the BTG level and fetal outcome. The significant increase in plasma BTG in PIH indicates enhanced platelet activation in these patients.

Adult↗

Vascular problems in paroxysmal nocturnal haemoglobinuria. A report of two cases.

Two patients with paroxysmal nocturnal haemoglobinuria (PNH) are described who had severe vascular complications. The first patient developed extensive thrombosis of the abdominal veins leading to intractable ascites symptomatically treated with a peritoneo-venous shunt. The second patient had aneurysm of the abdominal aorta treated with a prosthetic graft. Although in both patients prosthetic grafts were implanted no signs of an increased activation of the P.N.H. cells were found and no thrombosis or severe haemolytic anaemia occurred. It is suggested that surgical intervention for vascular complications in PNH should not be delayed because of fear of activating the PNH.

Adult↗

A study of the cellular and humoral immune response in patients with myelofibrosis.

There was evidence of impaired cellular immunity in 10 patients with myelofibrosis. In-vitro lymphocyte transformation with phytohaemagglutin, concanavalin A, and dinitrochlorobenzene skin reaction were diminished. Signs of impaired humoral activity were also found, the primary response to alpha-Helix pomatia haemocyanin being impaired, particularly in the immunoglobulin-A class. Moreover three patients had a benign paraproteinaemia. Immunecomplexes (IC) could be demonstrated with various test systems. The indirect granulocyte phagocytosis test was positive in 50%, the C1q-binding in 70% and the polyethylene glycol precipitation test in 50%. In most patients complement levels were normal, although the patient with the most advanced disease had low C3A, C3 and C4 levels accompanied by high levels of IC. No correlation could be shown between impaired immune response or levels of IC when they were related to spleen diameter or degree of anaemia. Some relation however existed between disturbed immune response and IC when they were related to time elapsed since diagnosis. It is suggested that the impaired immune response is the result of primary bone marrow disease and that the presence of IC may reflect the extent of fibrosis.

Antibody Formation↗

A familial hemorrhagic diathesis in a Dutch family: an inherited deficiency of alpha 2-antiplasmin.

This study concerns a case of congenital homozygous deficiency in alpha 2-antiplasmin associated with a severe hemorrhagic diathesis. Heterozygous family members also show a mild bleeding tendency. The propositus is a 17-yr-old male born of white parents and showing a severe hemorrhagic diathesis characterized by spontaneous bleeding in the joints since his early childhood. He was originally suspected of having factor XIII deficiency but was found to have normal functions of the coagulation system and the platelets. Except for alpha 2-antiplasmin, all protease inhibitors showed normal plasma values. With the immediate plasmin inhibition test (synthetic substrate), only 2% of normal functional inhibition was detected, while no reaction with monospecific antisera for alpha 2-antiplasmin was observed. Inhibition of activator-induced fibrinolysis in vitro was reduced. No enhanced spontaneous in vitro fibrinolysis was detected nor were there signs of increased in vivo fibrinolysis during an asymptomatic period. During recovery from a hemorrhagic episode, signs of previous consumption of antithrombin III, alpha 2-macroglobulin, factor XIII, and inter-alpha-trypsin inhibitor were noted. After the diagnosis was made, treatment with tranexamic acid (4 daily doses of 1 g) was effective for about 2 yr. Among the 37 family members studied, a separate group of 16 individuals (including the father and mother of the propositus) with approximately one-half normal plasma levels of alpha 2-antiplasmin both functionally (59% +/- 6%) and immunologically 48% +/- 8%) was discovered. The defect appeared to be inherited as an autosomal recessive gene; no ancestral consanguinity could be shown. The group of apparent heterozygotes as a whole showed increased levels of alpha 1-antitrypsin (142% +/- 39%; p less than 0.01), indicating systemic consequences of the deficiency and reduced binding (+/- 50%) of alpha 2-antiplasmin to fibrin. Six exhibited a mild hemorrhagic diathesis for which no explanation was provided by routine screening of coagulation and platelet functions; also, within the group of heterozygotes, the occurrence of the bleeding tendency did not correlate with differences in residual alpha 2-antiplasmin levels and functions. It is concluded that not only the absence of alpha 2-antiplasmin but also a reduction in its plasma level to +/- 60% of normal may predispose to a hemorrhagic diathesis.

Adolescent↗

Immunological dysfunction in paroxysmal nocturnal haemoglobinuria.

In five patients with paroxysmal nocturnal haemoglobinuria (PNH) immune capacity was tested. We found impaired in-vitro lymphocyte proliferation after stimulation with allogenic lymphocytes and concanavalin A (con A) in different concentrations. This suggests a disturbed T-cell immunity in these patients, although the number of T cells were normal. As the response to phytohaemagglutin (PHA) stimulation was adequate in most patients, it is presumed that a part of the T-cell population remains normal, as is also suggested by a normal in-vivo response to dinitrochlorobenzene (DNCB). Normal immunoglobulin (Ig) levels and normal anti Helix pomatia haemocyanin (HPH) antibody response were found in most patients. Some patients showed a very low response to pokeweed mitogen (PWM), suggesting some disturbance in the B cell capacity. The decreased number of B cells, found in all patients may also be attributed to this dysfunction. Exposure to inulin enhances the in-vitro effect in lymphocytes of patients with PNH. This indicates functional damage in a population of lymphocytes, possibly originating from an abnormal cell clone with the PNH characteristics. It is therefore suggested that the immunological disturbances could be caused by the primary bone marrow disease.

Adult↗

Normal levels of antithrombin III in acute leukemia complicated by coagulopathy.

A patient with acute monoblastic leukemia developed a coagulopathy during chemotherapy. Coagulation studies showed thrombocytopenia, hypofibrinogenemia, high levels of fibrinogen degradation products, a negative protemine test but a normal antithrombin III level. These observations suggest that coagulation abnormalities appearing in acute leukemia are not necessarily due to diffuse intravascular coagulation.

Acute Disease↗

Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma.

BACKGROUND: Associations of Hodgkin's lymphoma with HLA have been reported for many years. In 20-40% of patients with this disorder, Epstein-Barr virus (EBV) is present in the neoplastic cells. Because presentation of EBV antigenic peptides can elicit vigorous immune responses, we investigated associations of the HLA region with EBV-positive and EBV-negative Hodgkin's lymphoma. METHODS: In a retrospective, population-based study, patients with Hodgkin's lymphoma were reclassified according to the WHO classification, and EBV status was assessed by in-situ hybridisation of EBV-encoded small RNAs. Germline DNA was isolated from 200 patients diagnosed between 1987 and 2000 and from their first-degree relatives. Genotyping was done with 33 microsatellite markers spanning the entire HLA region and two single-nucleotide polymorphisms in the genes for tumour necrosis factor alpha and beta. Classic association analysis and the haplotype sharing statistic were used to compare patients with controls. FINDINGS: Classic association analysis (but not the haplotype sharing statistic) showed an association of consecutive markers D6S265 and D6S510 (p=0.0002 and 0.0003), located in the HLA class I region, with EBV-positive lymphomas. The haplotype sharing statistic (but not classic association analysis) showed a significant difference in mean haplotype sharing between patients and controls surrounding marker D6S273 (p=0.00003), located in HLA class III. INTERPRETATION: Areas within the HLA class I and class III regions are associated with susceptibility to Hodgkin's lymphoma, the association with class I being specific for EBV-positive disease. This finding strongly suggests that antigenic presentation of EBV-derived peptides is involved in the pathogenesis of EBV-involved Hodgkin's lymphoma. RELEVANCE TO PRACTICE: Polymorphisms in the HLA region could explain ethnic variation in the incidence of Hodgkin's lymphoma. The association of EBV-positive Hodgkin's lymphoma with HLA class I suggests that this polymorphism might affect the proper presentation of EBV antigens to cytotoxic T lymphocytes.

Adolescent↗

The role of oral mucositis on the systemic inflammation parameter IL-8 in febrile neutropenic cancer patients.

PURPOSE: Cancer patients treated with cytostatic drugs often develop oral mucositis, considered to be a mucosal injury in which various cytokines, such as interleukin 8 (IL-8), may play a role. Plasma IL-8 is a systemic inflammatory response parameter. This study investigated whether oral mucositis affects plasma IL-8 levels in febrile neutropenic cancer patients. PATIENTS AND METHODS: Patients (n = 57) who were hospitalized with chemotherapy-induced neutropenic fever were scored for oral mucositis on the second day of hospitalization according to a validated oral mucositis assessment scale (OMAS) and WHO toxicity grading. Patients (n = 20) with a clinical sepsis or local bacterial infection were excluded from this evaluation. The remaining 37 patients were divided in groups with and without oral mucositis. RESULTS: The difference in plasma IL-8 level between patients with and without mucositis was not significant (P = 0.7). Similarly no difference was observed in the degree and duration of granulocytopenia. CONCLUSION: These results indicate that low-grade oral mucositis is not related to the systemic plasma IL-8 level in febrile neutropenic cancer patients without a clinical sepsis or local bacterial infection.

Adolescent↗